Owers Corinne E, Vaughan Paul, Braidley Peter C, Wilkinson Glen A L, Locke Timothy J, Cooper Graham J, Briffa Norman P, Hopkinson David N, Sarkar Pradip K
Department of Cardiothoracic Surgery, Northern General Hospital, Herries Road, Sheffield, United Kingdom.
Heart Surg Forum. 2011 Apr;14(2):E105-9. doi: 10.1532/HSF98.20101163.
Although an atrial myxoma is the commonest cardiac tumor, it is still relatively rare, with an annual incidence of approximately 0.5 per million. In our unit, which performs 1000 major cardiac procedures per year, this equates to approximately 3 patients annually. We therefore sought to evaluate our experience of managing this type of tumor over the last 5 years.
A retrospective review was performed of prospectively collected data from the departmental database. We analyzed consecutive patients who were operated upon between 2002 and 2007. Three patients with a papillary fibroelastoma on histological examination were excluded from this study.
We have performed excision of atrial myxoma in 18 patients. Twelve patients (66%) were female; the median age was 64 years (range, 35-80 years), and the median logistic euroSCORE was 5.22% (range, 1.51-27.82%). Fifteen patients (83%) were deemed urgent, 2 elective, and 1 emergency. Sixteen tumors (89%) were left sided. Symptoms attributable to the tumor were found in 16 of the 18 patients (embolic, n = 9; chest pain, n = 3; palpitations, n = 2; incidental finding, n = 2, others n = 4), and the mean time from diagnosis to operation was 3 days (range, 0-22 months). The median cardiopulmonary bypass time was 87 minutes (range, 28-228 minutes), with the median aortic cross clamp time being 61 minutes (16-175 minutes).The approaches used were transeptal via right atriotomy (n = 8), biatrial/Dubost (n = 4), left atrial (n = 4), and right atrial (n = 2); the interatrial septum was involved in 14 patients. The resultant defect was closed using a pericardial (n = 8) or prosthetic patch (n = 5) or directly sutured (n = 5). Concomitant procedures were performed in 8 patients (coronary artery bypass graft [CABG], n = 4; mitral valve replacement [MVR], n = 2; valve + grafts, n = 2). All tumors were completely excised.Postoperatively there were no deaths within 30 days of the procedure. Indeed, only 2 patients have died at 4 and 25 months postoperatively, respectively, both of unrelated causes. Median intensive therapy unit (ITU) stay was 2 days (range, 1-9 days), and median hospital stay was 10 days (range, 5-20 days). A permanent pacemaker was required in only 1 patient, and median blood loss was 340 mL (range, 140-1760 mL). Atrial fibrillation was the commonest complication affecting 6/18 patients (33%).
Excision of atrial myxoma can be performed using a variety of intraoperative approaches and closure techniques, all with acceptable postoperative morbidity and low mortality rates. To date, no recurrences have been found at median 2-year follow-up.
尽管心房黏液瘤是最常见的心脏肿瘤,但仍然相对罕见,年发病率约为百万分之0.5。在我们每年进行1000例心脏大手术的科室,这相当于每年约3例患者。因此,我们试图评估过去5年中我们处理这类肿瘤的经验。
对前瞻性收集的科室数据库数据进行回顾性分析。我们分析了2002年至2007年间连续接受手术的患者。组织学检查为乳头状纤维弹性瘤的3例患者被排除在本研究之外。
我们为18例患者实施了心房黏液瘤切除术。12例患者(66%)为女性;中位年龄为64岁(范围35 - 80岁),中位逻辑欧洲心脏手术风险评估系统(EuroSCORE)为5.22%(范围1.51 - 27.82%)。15例患者(83%)为急诊手术,2例为择期手术,1例为急诊手术。16个肿瘤(89%)位于左侧。18例患者中有16例出现了与肿瘤相关的症状(栓塞,9例;胸痛,3例;心悸,2例;偶然发现,2例,其他4例)从诊断到手术的平均时间为3天(范围0 - 22个月)。中位体外循环时间为87分钟(范围28 - 228分钟),中位主动脉阻断时间为61分钟(16 - 175分钟)。采用的手术入路包括经右心房切开的经房间隔入路(8例)、双心房/Dubost入路(4例)、左心房入路(4例)和右心房入路(2例);14例患者的房间隔受累。使用心包补片(8例)、人工补片(5例)或直接缝合(5例)关闭由此产生的缺损。8例患者同时进行了其他手术(冠状动脉旁路移植术[CABG],4例;二尖瓣置换术[MVR],2例;瓣膜 + 移植,2例)。所有肿瘤均被完全切除。术后30天内无死亡病例。实际上,只有2例患者分别在术后4个月和25个月死亡,均为非相关原因。中位重症监护病房(ITU)住院时间为2天(范围1 - 9天),中位住院时间为10天(范围5 - 20天)。仅1例患者需要植入永久性起搏器,中位失血量为340毫升(范围140 - 1760毫升)。心房颤动是最常见的并发症,影响6/18例患者(33%)。
心房黏液瘤切除术可采用多种术中入路和关闭技术,术后发病率均可接受,死亡率较低。迄今为止,在中位2年的随访中未发现复发情况。